

12-18-01

A

Patent

Attorney Docket: 24001-010:

To: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

12/14/01
10/016969
U.S. PTO

NEW APPLICATION TRANSMITTAL - UTILITY

Sir:

Transmitted herewith for filing is a **utility** patent application:**Inventor(s):** Richard A. Pittner, Andrew A. Young and James R. Paterniti**Title:** PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METOBOLIC DISORDERS**I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):**

30 Page(s) of Written Description
3 Page(s) Claims
1 Page(s) Abstract
8 Sheets of Drawings ☐ Informal ☒ Formal

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

☒ Declaration
☐ Power of Attorney ☐ Separate ☐ Combined with Declaration
☒ Assignment to Amylin Pharmaceuticals, Inc. and assignment cover sheet
☐ Certified Copy of Priority Document No(s): _____
☐ Information Disclosure Statement w/PTO 1449 ☐ Copy of Citations
☐ Preliminary Amendment
☐ Request and Certification under 35 U.S.C. § 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35
☒ Return Postcard
☒ Other: Sequence Listing, Statement and Diskette

3 pages

CERTIFICATE OF EXPRESS MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as "Express Mail-Post Office to Addressee" in an envelope addressed to the Assistant Commissioner for Trademarks, Washington, D.C. 20231.

ET 577725132 US
Express Mail Number

Name of Person Mailing Paper

December 14, 2001
Date of Deposit

Signature of Person Mailing Paper

III. PRIORITY

- ☒ Priority of application Serial No. 60/256,216 filed on December 14th in 2000 is claimed under 35 .S.C. § 119.

IV. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

- ☒ Applicant claims small entity status pursuant to 37 CFR § 1.27

BASIC FILING FEE:							740.00
Total Claims	38	-	20	=	18	x \$18.00	321.00
Independent Claims	5	-	3	=	20	x \$80.00	160.00
Multiple Dependent Claims	\$270	(if applicable)				<input checked="" type="checkbox"/>	270.00
TOTAL OF ABOVE CALCULATIONS							1491.00
Reduction by ½ for Filing by Small Entity, if applicable, as asserted above. Note 37 CFR §§ 1.9, 1.27, 1.28.							<input checked="" type="checkbox"/> 745.00
Misc. Filing Fees (Recordation of Assignment -- \$40)							40.00
TOTAL FEES DUE HERewith							785.00

V. METHOD OF PAYMENT OF FEES

- ☐ A check in the amount of _____.
- ☒ Charge Amylin Pharmaceutical, Inc.'s Deposit Account No. 010535 in the amount of \$785.00.
- ☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

VI. AUTHORIZATION TO CHARGE FEES

The Commissioner is authorized to credit any overpayment and to charge any underpayment to Amylin Pharmaceuticals, Inc. Deposit Account No. 010535 for the following:

- ☒ 37 CFR § 1.16 – (Filing fees and excess claims fees)
- ☒ 37 CFR § 1.17 – (Any application processing fees)
- ☒ 37 CFR § 1.21 – (Assignment recording fees)

VII. CORRESPONDENCE ADDRESS

Please send all correspondence to:

Molly A. Holman, Ph.D.
Amylin Pharmaceuticals, Inc.
9373 Towne Centre Drive
San Diego California 92121

Please direct all inquiries to Molly A. Holman, Ph.D.

Respectfully submitted,

AMLYIN PHARMACEUTICALS, INC.

Dated: December 14, 2001

By: 

Molly A. Holman, Ph.D.
Registration No.: 40,022

Amylin Pharmaceuticals, Inc.
9373 Towne Centre Drive
San Diego, California
Telephone: (858) 552-2200
Facsimile: (858) 552-1936

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard R. Pittner, et al.

Serial No.: Not Yet Assigned

Filed: Herewith

Title: PEPTIDE YY AND PEPTIDE YY
AGONISTS FOR TREATMENT OF
METABOLIC DISORDERS

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING

Applicants submit herewith the "Sequence Listing" in paper copy and in computer readable form as required under s 1.824a.

The Sequence Listing is provided in ASCII text on the accompanying diskette. As required under 37 CFR s1.821f, the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing paper copy.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC

Molly A. Holman, Ph.D.

Registration No.: 40,022

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as "Express Mail-Post Office to Addressee" in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

ETS 7772513245
Express Mail Number

December 14, 2001
Date of Deposit

Amanda Halverson
Name of Person Mailing Paper

Amanda Halverson
Signature of Person Mailing Paper